Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710890 | 0.86 | KIF11 (0.51) | KIF11MEN1KMT2ACDK8SCN9A | |
| SCHEMBL18697357 | 0.86 | CDK8 (0.44) | CDK8HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL17352128 | 0.86 | CDK8 (0.44) | CDK8HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL17352175 | 0.86 | CDK8 (0.44) | CDK8HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL17352150 | 0.83 | MAOB (0.45) | CDK8HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL1893249 | 0.83 | LMNA (0.44) | KIF11MEN1KMT2ACDK8HTR2A | |
| SCHEMBL17356406 | 0.83 | CDK8 (0.42) | CDK8HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL17352125 | 0.83 | MAOB (0.45) | CDK8HTR2ASLC6A4KCNH2KMO | |
| SCHEMBL17352167 | 0.81 | MAPT (0.44) | KMT2ACDK8HTR2ASLC6A4KCNH2 | |
| SCHEMBL17356472 | 0.81 | CDK8 (0.44) | CDK8HTR2ASLC6A4KCNH2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213102-A1 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-07-07 | — | — | US | disclosed |
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | Janssen Science Ireland Unlimited Company (IE) | 2022-05-05 | — | — | US | disclosed |
| EP-3976616-A1 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| CN-114057739-A | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-109843892-B | Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections | 诺维拉治疗公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113939512-A | Fused heterocyclic derivatives as antiviral agents | 爱尔兰詹森科学公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113939511-A | Difluoroazepane as HBV capsid assembly modulators | 爱尔兰詹森科学公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113906028-A | Fused heterocyclic derivatives | 爱尔兰詹森科学公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-113906031-A | Fused heterocyclic derivatives as capsid assembly modulators | 爱尔兰詹森科学公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-113891889-A | Diazepinone derivatives as capsid assembly modulators | 爱尔兰詹森科学公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113631538-A | Novel potassium channel inhibitors | 萨尼奥纳有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109641896-B | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243142-A1 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239863-A1 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239862-A1 | DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| EP-3728272-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111511747-A | Isoxazole compounds for the treatment of diseases associated with HBV infection | 爱尔兰詹森科学公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-109641896-A | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | 诺维拉治疗公司 | 2019-04-16 | — | — | CN | disclosed |
| WO-2010103381-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES AS TRPM 8 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213102-A1 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | BAZ2A, BAZ2B, BAZ1A | KIF11 3039/4885MEN1 2173/4885KMT2A 1825/4885 |
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | HAVCR2, XDH, PYGL | KIF11 4572/4885MEN1 3773/4885KMT2A 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.